Aarti Pharma Labs Intrinsic Value
Aarti Pharma Labs (AARTIPHARM) median intrinsic value is ₹350.38 from 9 valuation models (range ₹210–₹1002), vs current price ₹700.75 — -50.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit AARTIPHARM screener.
AARTIPHARM Valuation Methods Summary — DCF, Graham Number & P/E
Aarti Pharma Labs intrinsic value across 9 models vs current price ₹700.75 — upside/downside and value range per method. Also explore AARTIPHARM stock price history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹271.04 | ₹216.83 - ₹325.25 | -61.3% | EPS: ₹12.32, Sector P/E: 22x |
| Book Value Method | asset | ₹884.44 | ₹796.00 - ₹972.88 | +26.2% | Book Value/Share: ₹442.22, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹743.11 | ₹668.80 - ₹817.42 | +6.0% | Revenue/Share: ₹371.56, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹657.78 | ₹592.00 - ₹723.56 | -6.1% | EBITDA: ₹296.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1002.15 | ₹801.72 - ₹1202.58 | +43.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹210.22 | ₹189.20 - ₹231.24 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹210.22 | ₹189.20 - ₹231.24 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹350.38 | ₹315.34 - ₹385.42 | -50.0% | ROE: 5.6%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹350.12 | ₹315.11 - ₹385.13 | -50.0% | EPS: ₹12.32, BVPS: ₹442.22 |
AARTIPHARM Intrinsic Value vs Market Price — All Valuation Models
Aarti Pharma Labs fair value range ₹210–₹1002 vs current market price ₹700.75 across 9 valuation models. Browse AARTIPHARM income statement for revenue, profit, balance sheet and cash flow data.
AARTIPHARM Intrinsic Value Analysis — Undervalued or Overvalued?
Aarti Pharma Labs median intrinsic value ₹350.38, current price ₹700.75 — Trading Above Calculated Value by 50.0%, margin of safety -100.0%.
What is the intrinsic value of AARTIPHARM?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Aarti Pharma Labs (AARTIPHARM) is ₹350.38 (median value). With the current market price of ₹700.75, this represents a -50.0% variance from our estimated fair value.
The valuation range spans from ₹210.22 to ₹1002.15, indicating ₹210.22 - ₹1002.15.
Is AARTIPHARM undervalued or overvalued?
Based on our multi-method analysis, Aarti Pharma Labs (AARTIPHARM) appears to be trading above calculated value by approximately 50.0%.
AARTIPHARM Financial Health — Key Ratios vs Industry Benchmarks
Aarti Pharma Labs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.10 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.58x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
AARTIPHARM Cash Flow Quality — Operating & Free Cash Flow
Aarti Pharma Labs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹332 Cr | ₹125 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹216 Cr | ₹109 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹250 Cr | ₹171 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-44 Cr | ₹-114 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |